NCT03028012 is a Phase 4 clinical trial of Ketorolac in Myofascial Pain, sponsored by University of Utah.

Who is sponsoring NCT03028012?

NCT03028012 is sponsored by University of Utah.

What drugs are being tested in NCT03028012?

Interventions in NCT03028012: Ketorolac, Lidocaine, Dexamethasone.

What condition does NCT03028012 study?

NCT03028012 studies Myofascial Pain.

Is NCT03028012 still recruiting?

NCT03028012 is currently terminated. Last updated 18 November 2020.

Are results published for NCT03028012?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-11-18 · How we verify

NCT03028012

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TPI Medication Comparison - Ketorolac, Lidocaine, or Dexamethasone

Terminated Phase 4 Results posted Last updated 18 November 2020

What this trial tests

Phase 4 trial testing Ketorolac in Myofascial Pain in 10 participants. Terminated before completion.

Timeline

2 May 2017

Primary endpoint
1 May 2019

1 May 2019

Quick facts

Lead sponsor	University of Utah
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	10
Start date	2 May 2017
Primary completion	1 May 2019
Estimated completion	1 May 2019
Sites	1 location across United States

Drugs / interventions tested

Ketorolac (KETOROLAC) — full drug profile →
Lidocaine — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →

Conditions studied

Myofascial Pain — all drugs for Myofascial Pain →

Sponsor

University of Utah

Who can join

Adults 18 to 100, any sex, with Myofascial Pain. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With a Responder Rate Greater Than 50% on the Numeric Rating Pain Scale (NRS) Improvement Primary · Pre-Post Injections Up to Three Months

Participants in this study underwent TPIs by the following method. The needle was inserted into the trigger point with the goal of eliciting a local twitch responses(LTRs). When a LTR was obtained, 0.1mL of randomized drug was injected into that location within the muscle. This was repeated until LTRs disappeared, or 1.0mL had been injected, whichever came first. This was performed in a similar manner for all affected muscles, up to a maximum of 2mL. Participants self-report their brief pain inventory at each of their injections (up to four subsequent injections) based off of the standardized

Group	Value	95% CI
Ketorolac	1
Lidocaine	0
Dexamethasone	0

Numeric Rating Pain Scale (NRS) at Baseline and Three Months. Secondary · Pre-Injection and Three Month Post Injection(s)

TPI were treated with a needle inserted into the trigger point with the goal of eliciting a local twitch responses(LTRs). When a LTR was obtained, 0.1mL of randomized drug was injected into that location within the muscle. This was repeated until LTRs disappeared, or 1.0mL had been injected, whichever came first. Such was performed in a similar manner for all affected muscles, up to a maximum of 2mL. Participants self-report their brief pain inventory at each of their injections (up to four subsequent injections) based off of the standardized Numeric Rating pain Scale (NRS). The NRS is nationa

Participant Number 3 at Baseline

Group	Value	95% CI
Ketorolac	8

Participant Number 3 at 3 Months

Group	Value	95% CI
Ketorolac	3

Participant Number 8 at Baseline

Group	Value	95% CI
Ketorolac	5

Participant Number 8 at 3 Months

Group	Value	95% CI
Ketorolac	3

Brief Pain Inventory (BPI) - Modified Secondary · Baseline and Three Months

The BPI was evaluated on a scale from 0-10. Zero would mean no interference and 10 would be calculated at complete interferences. We used a 7-point questionnaire about pain. All scores were calculated at baseline and three months.

Participant Number #3 at Baseline

Group	Value	95% CI
Ketorolac	8

Participant Number #3 at 3 Months

Group	Value	95% CI
Ketorolac	3

Participant Number #8 at Baseline

Group	Value	95% CI
Ketorolac	5

Participant #8 at 3 Months

Group	Value	95% CI
Ketorolac	3

Sponsor's own description

Hypothesis The main hypothesis of this study is that anti-inflammatory medications (ketorolac or dexamethasone) will provide longer-lasting and greater pain relief than just lidocaine in trigger point injections where a local twitch response is evoked at the time of the injection. Purpose/Specific Aims The primary objective of this study is to compare the efficacy of three substances used in TPIs with a LTR identified at the time of the injection: a CS (dexamethasone), a NSAID (ketorolac), or only a local anesthetic (lidocaine).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ketorolac

Trials testing the same drug.

NCT07487246 — Paracervical Block With Combined Ketorolac and Lidocaine for Osmotic Dilator Placement · Phase 2 · not yet recruiting
NCT07430085 — Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKA · Phase 4 · not yet recruiting
NCT06994442 — Optimizing Pain Treatment in Children On Mechanical Ventilation · Phase 3 · recruiting
NCT06968806 — Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection · Phase 3 · recruiting
NCT06973785 — Non-Narcotic Pain Control After ACL Reconstruction · Phase 3 · recruiting

Other recruiting trials for Myofascial Pain

Currently open trials in the same condition.

NCT07278570 — Magnetic Resonance Elastography to Monitor Response to Manual Therapy in Myofascial Pain · NA · recruiting
NCT06036524 — Multi-modal Imaging of Myofascial Pain · NA · active not recruiting
NCT05793086 — Evaluation of a Novel Class of Objective Myofascial Pain Assessments · active not recruiting

Other University of Utah trials

Trials by the same sponsor.

NCT07515755 — Supplemental Oxygen and Oxygen Desaturations in Colonoscopies · NA · not yet recruiting
NCT07225426 — Personalizing Financial Incentives · NA · recruiting
NCT06716411 — Confirming the Effects of Acupuncture Treatments to Relieve Symptoms of Gulf War Illness · NA · recruiting
NCT07246538 — Positive Airway Pressure (PAP) System Evaluation in Volunteers · NA · not yet recruiting
NCT04208984 — Diversion Device With Breath Control · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03028012 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Utah
Last refreshed: 18 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03028012.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing